984 related articles for article (PubMed ID: 28767550)
1. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
[TBL] [Abstract][Full Text] [Related]
3. The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.
Ceklic L; Huf W; Ebneter A; Wolf S; Zinkernagel MS; Munk MR
Acta Ophthalmol; 2019 Dec; 97(8):e1041-e1047. PubMed ID: 31099498
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
5. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
[TBL] [Abstract][Full Text] [Related]
6. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
7. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
Lee J; Moon BG; Cho AR; Yoon YH
Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
[TBL] [Abstract][Full Text] [Related]
8. Disorganization of the Retinal Inner Layers after Anti-VEGF Treatment for Macular Edema due to Branch Retinal Vein Occlusion.
Nakano E; Ota T; Jingami Y; Nakata I; Hayashi H; Yamashiro K
Ophthalmologica; 2018; 240(4):229-234. PubMed ID: 30089307
[TBL] [Abstract][Full Text] [Related]
9. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
[TBL] [Abstract][Full Text] [Related]
10. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema.
Lee H; Kang KE; Chung H; Kim HC
Jpn J Ophthalmol; 2019 May; 63(3):234-242. PubMed ID: 30783942
[TBL] [Abstract][Full Text] [Related]
12. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
Hsieh YT; Alam MN; Le D; Hsiao CC; Yang CH; Chao DL; Yao X
Ophthalmol Retina; 2019 Oct; 3(10):826-834. PubMed ID: 31227330
[TBL] [Abstract][Full Text] [Related]
13. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
14. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
15. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
17. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
[TBL] [Abstract][Full Text] [Related]
20. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]